TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33774942
Drug: Topical ozonated
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozonated sunflower oil
Study: 34772441
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic treatment after 2 weeks of IV antibiotic therapy
Study: 34772441
Drug: Standard 6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6-8 weeks of IV antibiotics
Study: 34772441
Drug: Standard IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IV antibiotics
Study: 35079029
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (INI) and Placebo
Study: 34509600
Drug: l-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-glutamine
Study: 35600633
Drug: AYUSH 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: AYUSH 64 (3 gm per day in three divided doses for 14 days)
Study: 33471548
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (77 Gy, fractions of 2.2 Gy)
Study: 34407771
Drug: Digital intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intervention and Treatment as usual
Study: 32192275
Drug: Ramosetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3 mg intravenously) combined with Aprepitant (125 mg orally, D1 and 80 mg orally, D2-3) and Dexamethasone (12 mg orally or intravenously, D1 and 8 mg orally, D2-4)
Study: 32192275
Drug: Palonosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.25 mg intravenously) combined with Aprepitant (125 mg orally, D1 and 80 mg orally, D2-3) and Dexamethasone (12 mg orally or intravenously, D1 and 8 mg orally, D2-4)
Study: 33419188
Drug: CRT (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT (50 Gy with oral capecitabine)
Study: 35612708
Drug: Finerenone 20
Normalized name: finerenone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 20 mg with high-fat, high-calorie meal
Study: 35612708
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg with omeprazole
Study: 35612708
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg with Maalox
Study: 34002953
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with pioglitazone plus exenatide or insulin
Study: 33091455
Drug: Nonsurgical endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical endodontic treatment (NSET)
Study: 33091455
Drug: Nonsurgical endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical endodontic treatment (NSET) combined with vital pulp therapy (VPT)
Study: 32563188
Drug: Dual trigger
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual trigger (GnRH agonist and hCG)
Study: 37723993
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil citrate, administered after onset of labor
Study: 33248439
Drug: Menthol energy
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol energy gel (0.5% concentration)
Study: 33248439
Drug: Menthol energy
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol energy gel (0.1% concentration)
Study: 33172865
Drug: Teprotumumab treatment
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teprotumumab treatment for 24 weeks
Study: 34929814
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera leaf capsules
Study: 34929814
Drug: TTD capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTD capsules
Study: 32907566
Drug: Navafenterol 400
Normalized name: Navafenterol
DrugBank: Navafenterol (DB19195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navafenterol 400 μg
Study: 32907566
Drug: Navafenterol 1800
Normalized name: Navafenterol
DrugBank: Navafenterol (DB19195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navafenterol 1800 μg
Study: 36343472
Drug: Automated virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated virtual reality therapy (gameChange)
Study: 33231847
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy group intervention (8 sessions)
Study: 36093920
Drug: Adalimumab adjunct
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab adjunct to sertraline
Study: 36093920
Drug: Placebo adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adjunct to sertraline
Study: 32360313
Drug: NACP on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACP on the base formulation (with 20 wt.% NACP)
Study: 32360313
Drug: NACP on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACP on the antibacterial formulation (with 20 wt.% NACP and 5 wt.% DMAHDM)
Study: 32360313
Drug: Base formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base formulation (without NACP and DMAHDM)
Study: 35438671
Drug: NLTX (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLTX (50 mg)
Study: 34218768
Drug: Pharmacist-led systematic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led systematic medication review
Study: 32017816
Drug: EEG Biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG Biofeedback therapy
Study: 38986575
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment plans
Study: 34923994
Drug: Aprepitant (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (80 mg daily)
Study: 34923994
Drug: Hydroxyzine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (25 mg daily)
Study: 36055414
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg caffeinated drink (CAF)
Study: 34477122
Drug: Standard lymphadenectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lymphadenectomy with postoperative adjuvant chemotherapy (SG)
Study: 34477122
Drug: Extended lymphadenectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended lymphadenectomy with postoperative adjuvant chemotherapy (EG)
Study: 33463088
Drug: Generic obeticholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic obeticholic acid (10 mg)
Study: 32573860
Drug: Tetrahydrocurcumin (THC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydrocurcumin (THC) 40 mg/kg for 3 days
Study: 32141126
Drug: Soluble dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble dietary fiber (SDF) 20-g/d polydextrose
Study: 32141126
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same EN solution without SDF)
Study: 35222874
Drug: Ultrasound-guided 18G-PTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided 18G-PTC puncture needle therapy
Study: 35222874
Drug: Small needle-knife
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small needle-knife therapy
Study: 34488841
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of colchicine
Study: 36942113
Drug: Buccal Mucosa
Normalized name: Diazepam 5 MG Buccal mucosa Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal Mucosa Graft Urethroplasty (Group B)
Study: 32090492
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) delivered on perineal area 5 minutes twice daily for 28 days
Study: 33176660
Drug: Traditional medications
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medications (RAAS blockers)
Study: 33176660
Drug: Dapagliflozin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin added to traditional medications
Study: 35118763
Drug: PACT (Physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACT (Physiotherapy informed by Acceptance and Commitment Therapy)
Study: 32433572
Drug: Chlorhexidine-chitosan gel
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-chitosan gel
Study: 32433572
Drug: Neutral water-based
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral water-based gel (placebo)
Study: 34348352
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 0.1% cream (BMV)
Study: 34348352
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate 1% cream (HC)
Study: 34348352
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate 0.1% cream (MPA)
Study: 34348352
Drug: Active agent-free
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active agent-free base cream (Dermatop® Basiscreme)
Study: 33509248
Drug: Regular knee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular knee arthroscopic therapy
Study: 35994013
Drug: Norepinephrine 0.05–0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.05–0.2 µg/kg/min
Study: 34323922
Drug: Chemoradiation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation and metformin
Study: 34568637
Drug: Quitline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quitline treatment as usual (TAU)
Study: 33271092
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of adjuvant chemotherapy (CAPOX or FOLFOX)
Study: 33271092
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of adjuvant chemotherapy (CAPOX or FOLFOX)
Study: 32376477
Drug: Preoperative resistance
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative resistance training (RT), twice a week for 10 weeks prior to THA
Study: 36294155
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (3 g/daily)
Study: 36294155
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil (3 g/daily)
Study: 34674300
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST), 2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis
Study: 32570775
Drug: Flavonoid-rich orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich orange juice (FR), 380 mL daily, 600 ± 5.4 mg flavonoids
Study: 32570775
Drug: Flavonoid-low orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-low orange cordial (FL), 380 mL daily, 108 ± 2.6 mg flavonoids
Study: 33303444
Drug: Goal-directed perfusion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) aimed to maintain DO2i at ≥360 mL/min/m2
Study: 32732515
Drug: Sacubitril/valsartan (Sal/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (Sal/Val) treatment
Study: 32732515
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment (Control)
Study: 36099671
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (CTX)
Study: 35380645
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) glucocorticoid injection (triamcinolone acetonide, 40 mg)
Study: 35380645
Drug: Intra-articular (IA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular (IA) glucocorticoid injection (triamcinolone acetonide, 40 mg)
Study: 33122571
Drug: Dexmedetomidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine with total intravenous anaesthesia (DEX‐TIVA)
Study: 32465270
Drug: <500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: <500 mg MMF/day
Study: 32465270
Drug: >2000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: >2000 mg MMF/day
Study: 32465270
Drug: All MMF
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All MMF dosing groups
Study: 32462307
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for anxiety in children with ADHD
Study: 34352138
Drug: Zuranolone 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuranolone 45 mg
Study: 33909356
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride capsule (20 mg once a day)
Study: 36476479
Drug: csDMARDs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARDs plus denosumab (60-mg subcutaneous injection once every 6 months for 12 months)
Study: 36476479
Drug: csDMARD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARD therapy alone
Study: 33289818
Drug: early high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: early high‐dose recombinant human erythropoietin (rhEpo)
Study: 32777456
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy educational tool with optional life expectancy information
Study: 32277868
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from protease inhibitors to rilpivirine (RPV)
Study: 32277868
Drug: Continue ritonavir-boosted
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continue ritonavir-boosted protease inhibitors (control group)
Study: 36476171
Drug: Remimazolam 5
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam 5 mg intravenously
Study: 36476171
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 µg/kg intravenously
Study: 36476171
Drug: Midazolam 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.025 mg/kg intravenously
Study: 32618713
Drug: Antenatal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal administration of uterotonics
Study: 34074611
Drug: Symptom-titrated, algorithm-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium)
Study: 34074611
Drug: Pharmacotherapy-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy-only
Study: 35840611
Drug: Probiotics, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics, daily doses, duration of 28 days
Study: 35840611
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily doses, duration of 28 days
Study: 32043304
Drug: Enteral hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral hydration (via NGT bolus, NGT continuous, both, or oral)
Study: 32043304
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids (IV)
Study: 32043304
Drug: Mix of
Normalized name: PHLEUM PRATENSE POLLEN 40000 [BAU] in 1 mL / DACTYLIS GLOMERATA POLLEN 20000 [BAU] in 1 mL / POA PRATENSIS POLLEN 20000 [BAU] in 1 mL / AGROSTIS GIGANTEA POLLEN 20000 [BAU] in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [MIDWEST MIX OF STANDARDIZED GRASS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix of NGT and oral hydration
Study: 33268143
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement (ONS) containing beta‐hydroxy‐beta‐methylbutyrate (HMB) with dietary counseling, two servings/day for 180 days.
Study: 33268143
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement with dietary counseling, two servings/day for 180 days.
Study: 33399351
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) expression in UC/DEAC
Study: 33399351
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) expression in FIGO 3 endometrioid carcinoma
Study: 33399351
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) expression in serous carcinoma
Study: 33399351
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) expression in carcinosarcoma
Study: 33399351
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) expression in clear cell carcinoma
Study: 33399351
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of AR expression with hormone receptors in UC/DEAC
Study: 33399351
Drug: Potential role
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential role of androgen inhibitors in management of UC/DEAC
Study: 35209785
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT), n=84
Study: 32048396
Drug: vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin 50 mg/day in addition to insulin
Study: 32048396
Drug: insulin-only group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin-only group
Study: 33131909
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy, diet and exercise
Study: 33559245
Drug: Magnesium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (200 mg) combined with 2 ml bupivacaine and 1 ml (40 mg) methylprednisolone
Study: 33559245
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 ml bupivacaine, 1 ml (40 mg) methylprednisolone and 1 ml saline (0.9%))
Study: 33369824
Drug: Analgesic treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic treatment and MET (Medical Expulsive Therapy)
Study: 34297066
Drug: Adipose tissue-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived stromal vascular fraction (AD-SVF) injection
Study: 34682824
Drug: Hyaluronic acid/trehalose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronic acid/trehalose ophthalmic solution (Thealoz® Duo) three times/day in the preoperative week and for 5 postoperative weeks (Group A)
Study: 34682824
Drug: Hyaluronic acid/trehalose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronic acid/trehalose ophthalmic solution (Thealoz® Duo) for only 5 postoperative weeks (Group B)
Study: 36065580
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) added to IPS
Study: 32827344
Drug: Automated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated oxygen administration using the FreeO2 device
Study: 32827344
Drug: Conventional manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional manual oxygen administration
Study: 32047601
Drug: Multiple visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple visit endodontic treatment with triple antibiotic paste interappointment dressing
Study: 32047601
Drug: Single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single visit endodontic treatment without interappointment dressing
Study: 34409931
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) alone
Study: 33395182
Drug: Low-volume plyometric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume plyometric training (40-60 ground contacts per session, twice weekly) in HV-1 group
Study: 33395182
Drug: Low-volume plyometric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume plyometric training (40-60 ground contacts per session, twice weekly) in VH-2 group
Study: 36184472
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (LTV), pressure controlled ventilation (PCV), respiratory rate (RR) 20‐to‐30/min, peak inspiratory pressure adjusted to keep tidal volume (Vt) 2 mL/kg
Study: 36344005
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen strategy (12-15 L O2/min or FiO2=0.6-1.0)
Study: 34226449
Drug: Econazole Nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole Nitrate 1% + Triamcinolone Acetonide 0.1% cream
Study: 32956782
Drug: HCQ/AZT combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ/AZT combination
Study: 32572664
Drug: HIPEC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC plus adjuvant chemotherapy
Study: 32464799
Drug: Extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal photopheresis plus standard immunosuppressive therapy (ECP)
Study: 33825723
Drug: Pletax® (cilostazol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pletax® (cilostazol) 100 mg twice daily
Study: 33825723
Drug: Trental® (pentoxifylline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trental® (pentoxifylline) 400 mg three times daily
Study: 34855311
Drug: H. psudoplicatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. psudoplicatum supplementation (250 mg/day for 6 weeks)
Study: 34855311
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg/day for 6 weeks)